Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough.

Muccino, David R; Morice, Alyn H; Birring, Surinder S; Dicpinigaitis, Peter V; Pavord, Ian D; Assaid, Christopher; Kleijn, Huub Jan; Hussain, Azher; La Rosa, Carmen; McGarvey, Lorcan; Smith, Jaclyn A

Muccino, David R; Morice, Alyn H; Birring, Surinder S; Dicpinigaitis, Peter V; Pavord, Ian D; Assaid, Christopher; Kleijn, Huub Jan; Hussain, Azher; La Rosa, Carmen; McGarvey, Lorcan; Smith, Jaclyn A.

Afiliação

Muccino DR; Merck & Co., Inc., Kenilworth, NJ, USA.
Morice AH; Hull York Medical School, Cottingham, UK.
Birring SS; Centre for Human and Applied Physiological Sciences, School of Basic and Medical Biosciences, King's College London, London, UK.
Dicpinigaitis PV; Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.
Pavord ID; Oxford NIHR Respiratory BRC, Nuffield Dept of Medicine, University of Oxford, Oxford, UK.
Assaid C; Merck & Co., Inc., Kenilworth, NJ, USA.
Kleijn HJ; Certara Strategic Consulting, Oss, The Netherlands.
Hussain A; Merck & Co., Inc., Kenilworth, NJ, USA.
La Rosa C; Merck & Co., Inc., Kenilworth, NJ, USA.
McGarvey L; Wellcome-Wolfson Institute of Experimental Medicine, Queen's University Belfast, Belfast, UK.
Smith JA; Division of Infection, Immunity and Respiratory Medicine, University of Manchester and Manchester University NHS Trust, Manchester, UK.

ERJ Open Res ; 6(4)2020 Oct.

Article em En | MEDLINE | ID: mdl-33263037

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Aspecto: Patient_preference Idioma: En Revista: ERJ Open Res Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google